Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.
• Subject must be ≥ 18 years.
• Patients with at least one target lesion meet CCTA-detected plaque features of the following:
‣ Degree of stenosis ≥ 50% or plaque burden ≥ 70%
⁃ At least 2 of the following high-risk plaque features:
• i. Low-attenuation plaque ii. Positive remodeling iii. Napkin-ring sign iv. Spotty calcium
• The target lesion is located at the proximal or mid segment of left anterior descending artery, left circumflex artery or right coronary artery.
• Subject is able to confirm his/her understanding of the risks, benefits, and treatment alternatives of receiving study-related treatment. He/she or his/her legally authorized representative provides written informed consent prior to any study-related procedure.